Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities... Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1 | 1 | 1 | 12000 | 1 | CS |
| 4 | -0.2 | -16.6666666667 | 1.2 | 1.23 | 1 | 104299 | 1.02786837 | CS |
| 12 | 0.0393 | 4.09076714895 | 0.9607 | 1.23 | 0.8314 | 44811 | 1.01036516 | CS |
| 26 | -0.11 | -9.90990990991 | 1.11 | 1.23 | 0.7384 | 23736 | 0.97175517 | CS |
| 52 | 0.55 | 122.222222222 | 0.45 | 1.23 | 0.45 | 15445 | 0.9627156 | CS |
| 156 | -0.5 | -33.3333333333 | 1.5 | 2.17 | 0.4011 | 9678 | 0.9848213 | CS |
| 260 | -0.99 | -49.7487437186 | 1.99 | 2.29 | 0.4011 | 8061 | 0.99758407 | CS |
knrorrel
2分前
ghostandgurgi
3分前
gdl
3分前
Curios George
3分前
Backstabbed
4分前
Jonjones325
4分前
Boston-Bets
5分前
franksaran
5分前
mr_sano
6分前
SovereignWarlock10
6分前
Mark
7分前
theRupertPupkin
7分前
jimr1717
7分前
jimr1717
8分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。